vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Unity Software Inc. (U). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $503.1M, roughly 1.2× Unity Software Inc.). Royalty Pharma plc runs the higher net margin — 34.4% vs -17.9%, a 52.3% gap on every dollar of revenue. On growth, Unity Software Inc. posted the faster year-over-year revenue change (10.1% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 4.5%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Unity Software Inc. is an American video game software development company based in San Francisco. It was founded in Denmark in 2004 as Over the Edge Entertainment and changed its name in 2007. Unity Technologies is best known for the development of Unity, a licensed game engine used to create video games and other applications.

RPRX vs U — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.2× larger
RPRX
$622.0M
$503.1M
U
Growing faster (revenue YoY)
U
U
+5.3% gap
U
10.1%
4.8%
RPRX
Higher net margin
RPRX
RPRX
52.3% more per $
RPRX
34.4%
-17.9%
U
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
4.5%
U

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RPRX
RPRX
U
U
Revenue
$622.0M
$503.1M
Net Profit
$214.2M
$-90.0M
Gross Margin
74.3%
Operating Margin
62.4%
-21.2%
Net Margin
34.4%
-17.9%
Revenue YoY
4.8%
10.1%
Net Profit YoY
2.9%
26.7%
EPS (diluted)
$0.49
$-0.21

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
U
U
Q4 25
$622.0M
$503.1M
Q3 25
$609.3M
$470.6M
Q2 25
$578.7M
$440.9M
Q1 25
$568.2M
$435.0M
Q4 24
$593.6M
$457.1M
Q3 24
$564.7M
$446.5M
Q2 24
$537.3M
$449.3M
Q1 24
$568.0M
$460.4M
Net Profit
RPRX
RPRX
U
U
Q4 25
$214.2M
$-90.0M
Q3 25
$288.2M
$-126.4M
Q2 25
$30.2M
$-108.8M
Q1 25
$238.3M
$-77.6M
Q4 24
$208.2M
$-122.7M
Q3 24
$544.0M
$-124.7M
Q2 24
$102.0M
$-125.6M
Q1 24
$4.8M
$-291.1M
Gross Margin
RPRX
RPRX
U
U
Q4 25
74.3%
Q3 25
74.4%
Q2 25
74.1%
Q1 25
73.8%
Q4 24
74.7%
Q3 24
74.9%
Q2 24
75.8%
Q1 24
68.6%
Operating Margin
RPRX
RPRX
U
U
Q4 25
62.4%
-21.2%
Q3 25
70.1%
-26.7%
Q2 25
36.3%
-26.9%
Q1 25
94.0%
-29.4%
Q4 24
60.9%
-27.1%
Q3 24
-28.5%
Q2 24
50.2%
-28.8%
Q1 24
-13.0%
-81.4%
Net Margin
RPRX
RPRX
U
U
Q4 25
34.4%
-17.9%
Q3 25
47.3%
-26.9%
Q2 25
5.2%
-24.7%
Q1 25
41.9%
-17.8%
Q4 24
35.1%
-26.8%
Q3 24
96.3%
-27.9%
Q2 24
19.0%
-28.0%
Q1 24
0.8%
-63.2%
EPS (diluted)
RPRX
RPRX
U
U
Q4 25
$0.49
$-0.21
Q3 25
$0.67
$-0.30
Q2 25
$0.07
$-0.26
Q1 25
$0.55
$-0.19
Q4 24
$0.46
$-0.30
Q3 24
$1.21
$-0.31
Q2 24
$0.23
$-0.32
Q1 24
$0.01
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
U
U
Cash + ST InvestmentsLiquidity on hand
$618.7M
$2.1B
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
$3.2B
Total Assets
$19.6B
$6.8B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
U
U
Q4 25
$618.7M
$2.1B
Q3 25
$938.9M
$1.9B
Q2 25
$631.9M
$1.7B
Q1 25
$1.1B
$1.5B
Q4 24
$929.0M
$1.5B
Q3 24
$950.1M
$1.4B
Q2 24
$1.8B
$1.3B
Q1 24
$843.0M
$1.2B
Total Debt
RPRX
RPRX
U
U
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
RPRX
RPRX
U
U
Q4 25
$9.7B
$3.2B
Q3 25
$9.6B
$3.2B
Q2 25
$9.5B
$3.2B
Q1 25
$9.8B
$3.2B
Q4 24
$10.3B
$3.2B
Q3 24
$10.3B
$3.2B
Q2 24
$9.8B
$3.2B
Q1 24
$9.9B
$3.2B
Total Assets
RPRX
RPRX
U
U
Q4 25
$19.6B
$6.8B
Q3 25
$19.3B
$6.8B
Q2 25
$18.3B
$6.7B
Q1 25
$17.6B
$6.6B
Q4 24
$18.2B
$6.7B
Q3 24
$18.0B
$6.7B
Q2 24
$17.7B
$6.7B
Q1 24
$16.1B
$6.8B
Debt / Equity
RPRX
RPRX
U
U
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
U
U
Operating Cash FlowLast quarter
$827.1M
$121.4M
Free Cash FlowOCF − Capex
$118.7M
FCF MarginFCF / Revenue
23.6%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$403.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
U
U
Q4 25
$827.1M
$121.4M
Q3 25
$702.6M
$155.4M
Q2 25
$364.0M
$133.1M
Q1 25
$596.1M
$13.0M
Q4 24
$742.5M
$112.2M
Q3 24
$703.6M
$122.4M
Q2 24
$658.2M
$88.4M
Q1 24
$664.6M
$-7.4M
Free Cash Flow
RPRX
RPRX
U
U
Q4 25
$118.7M
Q3 25
$151.3M
Q2 25
$126.7M
Q1 25
$7.3M
Q4 24
$105.8M
Q3 24
$115.2M
Q2 24
$79.6M
Q1 24
$-14.6M
FCF Margin
RPRX
RPRX
U
U
Q4 25
23.6%
Q3 25
32.1%
Q2 25
28.7%
Q1 25
1.7%
Q4 24
23.1%
Q3 24
25.8%
Q2 24
17.7%
Q1 24
-3.2%
Capex Intensity
RPRX
RPRX
U
U
Q4 25
0.5%
Q3 25
0.9%
Q2 25
1.5%
Q1 25
1.3%
Q4 24
1.4%
Q3 24
1.6%
Q2 24
2.0%
Q1 24
1.6%
Cash Conversion
RPRX
RPRX
U
U
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
3.57×
Q3 24
1.29×
Q2 24
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

U
U

Grow Solutions$338.2M67%
Create Solutions$164.9M33%

Related Comparisons